Erbitux and Altace drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Erbitux (cetuximab) and Altace (ramipril). Common drug interactions include malignant neoplasm progression among females and malignant neoplasm progression among males.

The phase IV clinical study analyzes what interactions people have when they take Erbitux and Altace. It is created by eHealthMe based on reports of 31 people who take the same drugs from the FDA, and is updated regularly.

What is Erbitux?

Erbitux has active ingredients of cetuximab. It is often used in cancer. eHealthMe is studying from 19,276 Erbitux users. Check the latest studies of Erbitux.

What is Altace?

Altace has active ingredients of ramipril. It is often used in high blood pressure. eHealthMe is studying from 23,681 Altace users. Check the latest studies of Altace.

On Jul, 11, 2026

31 people who take Erbitux and Altace together, and have interactions are studied.

What are the common drug interactions of Erbitux and Altace, by gender? *:

female:

Malignant neoplasm progression (cancer tumour came back)
Colon cancer
Blood pressure systolic increased
Cardiac failure congestive
Ill-defined disorder
Somnolence (a state of near-sleep, a strong desire for sleep)
Asthenia (weakness)
Blood calcium decreased
Blood magnesium decreased
Blood potassium decreased

male:

Malignant neoplasm progression (cancer tumour came back)
Dehydration (dryness resulting from the removal of water)
Infusion related reaction
Malaise (a feeling of general discomfort or uneasiness)
Pleural effusion (water on the lungs)
Pulse absent
Respiratory failure (inadequate gas exchange by the respiratory system)
Skin fissures (a crack in the skin)
Small intestinal obstruction (blockage in small intestine)
Dysphagia (a condition in which swallowing is difficult or painful)

What are the common drug interactions of Erbitux and Altace, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

Dehydration (dryness resulting from the removal of water)
Dysphagia (a condition in which swallowing is difficult or painful)
Flushing (the warm, red condition of human skin)
Pruritus (severe itching of the skin)
Syncope (loss of consciousness with an inability to maintain postural tone)
Anaphylactic reaction (serious allergic reaction)
Blindness
Dermatitis acneiform (dermatoses including acne vulgaris, rosacea, folliculitis, and perioral dermatitis)
Eye pain
Ocular hyperaemia (an abnormally large amount of blood in eye)

60+:

Malignant neoplasm progression (cancer tumour came back)
Colon cancer
Cardiac failure congestive
Coma (state of unconsciousness lasting more than six hours)
Dehydration (dryness resulting from the removal of water)
Dyspnoea (difficult or laboured respiration)
Hypotension (abnormally low blood pressure)
Ill-defined disorder
Pleural effusion (water on the lungs)
Rash

What are the existing conditions these people have? *

Colon Cancer: 12 people, 38.71%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 10 people, 32.26%
Pain: 4 people, 12.90%
High Blood Cholesterol: 4 people, 12.90%
Colorectal Cancer Metastatic (cancer of colon and rectal spreads to other parts): 3 people, 9.68%
Breast Cancer Metastatic: 3 people, 9.68%
Squamous Cell Carcinoma (a cancer of a kind of epithelial cell): 2 people, 6.45%
Sleep Disorder: 2 people, 6.45%
Rectal Cancer (cancer of rectum): 2 people, 6.45%
Rashes (redness): 2 people, 6.45%

* Approximation only. Some reports may have incomplete information.

Do you take Erbitux and Altace?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously